Researchers hunt for clues: why some blood cancer patients get hit harder by COVID-19
NCT ID NCT07204366
Summary
This study aims to understand why some patients with a group of blood cancers called MPNs experience severe COVID-19. Researchers are checking the blood of 219 MPN patients for specific proteins called autoantibodies that might weaken the body's early virus defense. The goal is to see if having these proteins is linked to worse COVID-19 outcomes in this patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.